Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP578445.RANVnQhC0Df9Zik-mFCLkDToe05gs1J_X8cYRYp_ceApg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP578445.RANVnQhC0Df9Zik-mFCLkDToe05gs1J_X8cYRYp_ceApg130_assertion type Assertion NP578445.RANVnQhC0Df9Zik-mFCLkDToe05gs1J_X8cYRYp_ceApg130_head.
- NP578445.RANVnQhC0Df9Zik-mFCLkDToe05gs1J_X8cYRYp_ceApg130_assertion description "[The CCS gene profile described here offers a rationale for the use of RTK inhibitors alone or in combination with chemotherapy, and supports further investigation of RTKs and their downstream signals.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP578445.RANVnQhC0Df9Zik-mFCLkDToe05gs1J_X8cYRYp_ceApg130_provenance.
- NP578445.RANVnQhC0Df9Zik-mFCLkDToe05gs1J_X8cYRYp_ceApg130_assertion evidence source_evidence_literature NP578445.RANVnQhC0Df9Zik-mFCLkDToe05gs1J_X8cYRYp_ceApg130_provenance.
- NP578445.RANVnQhC0Df9Zik-mFCLkDToe05gs1J_X8cYRYp_ceApg130_assertion SIO_000772 16470538 NP578445.RANVnQhC0Df9Zik-mFCLkDToe05gs1J_X8cYRYp_ceApg130_provenance.
- NP578445.RANVnQhC0Df9Zik-mFCLkDToe05gs1J_X8cYRYp_ceApg130_assertion wasDerivedFrom befree-20140225 NP578445.RANVnQhC0Df9Zik-mFCLkDToe05gs1J_X8cYRYp_ceApg130_provenance.
- NP578445.RANVnQhC0Df9Zik-mFCLkDToe05gs1J_X8cYRYp_ceApg130_assertion wasGeneratedBy ECO_0000203 NP578445.RANVnQhC0Df9Zik-mFCLkDToe05gs1J_X8cYRYp_ceApg130_provenance.